
Releases
Investors Face August Deadline in ADMA Biologics Securities Lawsuit
Investors who purchased ADMA Biologics, Inc. securities between August 9, 2024, and March 25, 2026, have until August 10, 2026, to file for lead plaintiff status. The class action lawsuit, initiated by The Rosen Law Firm, alleges that the company misled shareholders regarding its internal controls and revenue reporting.




























